|
ES2667729T3
(es)
|
2007-09-26 |
2018-05-14 |
Ucb Biopharma Sprl |
Fusiones de anticuerpos con doble especificidad
|
|
WO2010035012A1
(en)
*
|
2008-09-26 |
2010-04-01 |
Ucb Pharma S.A. |
Biological products
|
|
AU2010216152B2
(en)
|
2009-02-17 |
2015-05-14 |
Ucb Biopharma Sprl |
Antibody molecules having specificity for human OX40
|
|
GB0904214D0
(en)
|
2009-03-11 |
2009-04-22 |
Ucb Pharma Sa |
Biological products
|
|
CA2763488A1
(en)
*
|
2009-05-28 |
2010-12-02 |
Neil James Clarke |
Antigen-binding proteins
|
|
EP2435482B1
(en)
*
|
2009-05-28 |
2019-04-03 |
Glaxo Group Limited |
Antigen-binding proteins
|
|
US20120134984A1
(en)
*
|
2009-06-01 |
2012-05-31 |
Olga Lubman |
Molecules with extended half-lives and uses thereof
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
EP2475682B1
(en)
|
2009-09-10 |
2018-01-31 |
UCB Biopharma SPRL |
Multivalent antibodies
|
|
GB201005063D0
(en)
*
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
|
GB0920127D0
(en)
*
|
2009-11-17 |
2009-12-30 |
Ucb Pharma Sa |
Antibodies
|
|
GB201000467D0
(en)
*
|
2010-01-12 |
2010-02-24 |
Ucb Pharma Sa |
Antibodies
|
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
|
EP2545078A1
(en)
|
2010-03-11 |
2013-01-16 |
UCB Pharma, S.A. |
Pd-1 antibody
|
|
GB201005064D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
|
WO2012009544A2
(en)
*
|
2010-07-14 |
2012-01-19 |
Amgen Inc. |
Domain insertion immunoglobulin
|
|
CA2806252C
(en)
|
2010-07-29 |
2019-05-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
CN103459422A
(zh)
|
2010-11-24 |
2013-12-18 |
葛兰素集团有限公司 |
靶向hgf的多特异性抗原结合蛋白
|
|
US20130266567A1
(en)
|
2010-12-01 |
2013-10-10 |
Haren Arulanantham |
Anti-serum albumin binding single variable domains
|
|
GB201100282D0
(en)
|
2011-01-07 |
2011-02-23 |
Ucb Pharma Sa |
Biological methods
|
|
US10208349B2
(en)
|
2011-01-07 |
2019-02-19 |
Ucb Biopharma Sprl |
Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
|
|
CN103384682B
(zh)
|
2011-01-14 |
2017-04-12 |
Ucb医药有限公司 |
结合il‑17a和il‑17f的抗体分子
|
|
EP2710042A2
(en)
|
2011-05-16 |
2014-03-26 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
ES2758884T3
(es)
*
|
2011-06-24 |
2020-05-06 |
Stephen D Gillies |
Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas
|
|
MX348738B
(es)
|
2011-07-13 |
2017-06-27 |
Ucb Pharma Sa |
Cepa huesped bacteriana que expresa dsbc recombinante.
|
|
WO2013038156A1
(en)
|
2011-09-16 |
2013-03-21 |
Ucb Pharma S.A. |
Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
SG11201401649VA
(en)
*
|
2011-11-11 |
2014-07-30 |
Ucb Pharma Sa |
Albumin binding antibodies and binding fragments thereof
|
|
UA112203C2
(uk)
|
2011-11-11 |
2016-08-10 |
Юсб Фарма С.А. |
Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
|
|
GB201208367D0
(en)
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Biological product
|
|
GB201208370D0
(en)
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Antibodies
|
|
CN104884473B
(zh)
*
|
2012-05-22 |
2019-12-03 |
百时美施贵宝公司 |
Il-17a/f il-23双特异性抗体及其应用
|
|
EP2931750B8
(en)
*
|
2012-12-17 |
2021-11-03 |
Cell Medica Inc. |
Antibodies against il-1 beta
|
|
GB201223276D0
(en)
*
|
2012-12-21 |
2013-02-06 |
Ucb Pharma Sa |
Antibodies and methods of producing same
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
HRP20191865T1
(hr)
|
2013-01-14 |
2020-01-10 |
Xencor, Inc. |
Novi heterodimerni proteini
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
WO2014113510A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
RU2015140915A
(ru)
|
2013-02-26 |
2017-04-03 |
Роше Гликарт Аг |
Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
CA3093606A1
(en)
|
2013-03-15 |
2014-09-18 |
Xencor, Inc. |
Heterodimeric proteins for induction of t cells
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
WO2015006337A2
(en)
|
2013-07-08 |
2015-01-15 |
Nanjingjinsirui Science & Technology Biology Corporation |
Compositions and methods for increasing protein half-life in a serum
|
|
GB201315487D0
(en)
|
2013-08-30 |
2013-10-16 |
Ucb Pharma Sa |
Antibodies
|
|
JP6422977B2
(ja)
*
|
2013-08-30 |
2018-11-14 |
エイプリルバイオ カンパニー リミテッド |
抗血清アルブミンｆａｂエフェクター部分融合コンストラクト、およびその製造方法
|
|
WO2015048685A1
(en)
*
|
2013-09-30 |
2015-04-02 |
Becton, Dickinson And Company |
Blocking reagent compositions and methods of making and using the same
|
|
TR201802728T4
(tr)
|
2013-10-25 |
2018-03-21 |
Psioxus Therapeutics Ltd |
Heterolog genlerle donatılmış onkolitik adenovirüsler.
|
|
GB201320066D0
(en)
|
2013-11-13 |
2013-12-25 |
Ucb Pharma Sa |
Biological products
|
|
WO2015127288A1
(en)
|
2014-02-20 |
2015-08-27 |
Alder Biopharmaceuticals, Inc. |
Anti-acth antibodies and use thereof
|
|
EP3954713A3
(en)
|
2014-03-28 |
2022-03-30 |
Xencor, Inc. |
Bispecific antibodies that bind to cd38 and cd3
|
|
US10267806B2
(en)
|
2014-04-04 |
2019-04-23 |
Mayo Foundation For Medical Education And Research |
Isotyping immunoglobulins using accurate molecular mass
|
|
GB201406608D0
(en)
|
2014-04-12 |
2014-05-28 |
Psioxus Therapeutics Ltd |
Virus
|
|
GB201409558D0
(en)
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
|
GB201411320D0
(en)
|
2014-06-25 |
2014-08-06 |
Ucb Biopharma Sprl |
Antibody construct
|
|
GB201411420D0
(en)
*
|
2014-06-26 |
2014-08-13 |
Ucb Biopharma Sprl |
Antibody constructs
|
|
US9884921B2
(en)
|
2014-07-01 |
2018-02-06 |
Pfizer Inc. |
Bispecific heterodimeric diabodies and uses thereof
|
|
GB201412658D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
GB201412659D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
WO2016044811A1
(en)
*
|
2014-09-19 |
2016-03-24 |
City Of Hope |
COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Rα2
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
CN116333153A
(zh)
|
2014-11-26 |
2023-06-27 |
森科股份有限公司 |
结合cd3和肿瘤抗原的异二聚体抗体
|
|
EP3223907A2
(en)
|
2014-11-26 |
2017-10-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd38
|
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
|
WO2016166169A1
(en)
*
|
2015-04-17 |
2016-10-20 |
Spring Bioscience Corporation |
Antibodies, compositions, and immunohistochemistry methods for detecting c4.4a
|
|
GB201506869D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
|
GB201506870D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
|
BR112017023158A2
(pt)
|
2015-04-30 |
2018-07-24 |
Harvard College |
anticorpos anti-ap2 e agentes de ligação de antígeno para tratar distúrbios metabólicos
|
|
US10676723B2
(en)
|
2015-05-11 |
2020-06-09 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
GB201508180D0
(en)
|
2015-05-13 |
2015-06-24 |
Ucb Biopharma Sprl |
Antibodies
|
|
CN111234027A
(zh)
|
2015-05-21 |
2020-06-05 |
哈普恩治疗公司 |
三特异性结合蛋白质及使用方法
|
|
WO2016189045A1
(en)
|
2015-05-27 |
2016-12-01 |
Ucb Biopharma Sprl |
Method for the treatment of neurological disease
|
|
CN106188305A
(zh)
*
|
2015-06-01 |
2016-12-07 |
中山大学 |
具有融合至常规Fab片段的单域抗原结合片段的二价抗体
|
|
GB201510758D0
(en)
|
2015-06-18 |
2015-08-05 |
Ucb Biopharma Sprl |
Novel TNFa structure for use in therapy
|
|
IL302486A
(en)
|
2015-06-24 |
2023-06-01 |
Hoffmann La Roche |
Antibodies against the transnephrine receptor with adapted affinity
|
|
CN107849105B
(zh)
|
2015-07-06 |
2021-09-17 |
Ucb生物制药有限责任公司 |
Tau结合抗体
|
|
CA2991451A1
(en)
|
2015-07-06 |
2017-01-12 |
Ucb Biopharma Sprl |
Tau-binding antibodies
|
|
GB201601075D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies molecules
|
|
GB201601077D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibody molecule
|
|
GB201601073D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
JP6657392B2
(ja)
|
2015-10-02 |
2020-03-04 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗ヒトｃｄ２０／ヒトトランスフェリン受容体抗体及び使用方法
|
|
ES2885476T3
(es)
|
2015-10-05 |
2021-12-13 |
Ucb Biopharma Sprl |
Firmas moleculares para uso en diagnóstico y análisis de respuesta al tratamiento de enfermedades autoinmunes
|
|
JP6931648B2
(ja)
|
2015-10-27 |
2021-09-08 |
ユーシービー バイオファルマ エスアールエル |
抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法
|
|
GB201521382D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521383D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl And Ucb Celltech |
Method
|
|
GB201521389D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Method
|
|
GB201521393D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521391D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
KR20180085800A
(ko)
|
2015-12-07 |
2018-07-27 |
젠코어 인코포레이티드 |
Cd3 및 psma에 결합하는 이종이합체성 항체
|
|
GB201522394D0
(en)
|
2015-12-18 |
2016-02-03 |
Ucb Biopharma Sprl |
Antibodies
|
|
SG11201805422WA
(en)
|
2016-01-11 |
2018-07-30 |
Inhibrx Inc |
Multivalent and multispecific ox40-binding fusion proteins
|
|
GB201602414D0
(en)
|
2016-02-10 |
2016-03-23 |
Nascient Ltd |
Biological materials and uses thereof
|
|
JP7034489B2
(ja)
|
2016-03-15 |
2022-03-14 |
アイタブメッド （エイチケイ） リミテッド |
多重特異性Ｆａｂ融合タンパクおよびその使用
|
|
WO2017191062A1
(en)
|
2016-05-01 |
2017-11-09 |
Ucb Biopharma Sprl |
Affinity engineered serum protein carrier binding domain
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
BR112018073739A2
(pt)
|
2016-05-20 |
2019-02-26 |
Harpoon Therapeutics, Inc. |
proteína de ligação de albumina sérica de domínio único
|
|
CN109641046B
(zh)
|
2016-05-20 |
2023-11-07 |
哈普恩治疗公司 |
单链可变片段cd3结合蛋白质
|
|
GB201610198D0
(en)
|
2016-06-10 |
2016-07-27 |
Ucb Biopharma Sprl |
Anti-ige antibodies
|
|
IL263542B2
(en)
|
2016-06-14 |
2024-10-01 |
Xencor Inc |
Bispecific antibodies inhibit immunological checkpoint
|
|
KR20190020341A
(ko)
|
2016-06-28 |
2019-02-28 |
젠코어 인코포레이티드 |
소마토스타틴 수용체 2에 결합하는 이종이량체 항체
|
|
UA128304C2
(uk)
|
2016-07-14 |
2024-06-05 |
Ґенмаб А/С |
Мультиспецифічне антитіло до cd40 і cd137
|
|
CN119614520A
(zh)
|
2016-08-29 |
2025-03-14 |
阿卡米斯生物公司 |
携带双特异性t细胞衔接器的腺病毒
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
CN110214148A
(zh)
|
2016-10-14 |
2019-09-06 |
Xencor股份有限公司 |
含有IL-15/IL-15Rα Fc融合蛋白和PD-1抗体片段的双特异性异源二聚体融合蛋白
|
|
WO2018083257A1
(en)
|
2016-11-03 |
2018-05-11 |
Psioxus Therapeutics Limited |
Oncolytic adenovirus encoding transgenes
|
|
WO2018083258A1
(en)
|
2016-11-03 |
2018-05-11 |
Psioxus Therapeutics Limited |
Oncolytic adenovirus encoding at least three transgenes
|
|
JP6812551B2
(ja)
|
2016-11-23 |
2021-01-13 |
ハープーン セラピューティクス，インク． |
前立腺特異的膜抗原結合タンパク質
|
|
JP7215997B2
(ja)
|
2016-11-23 |
2023-01-31 |
ハープーン セラピューティクス，インク． |
前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法
|
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
GB201621635D0
(en)
|
2016-12-19 |
2017-02-01 |
Ucb Biopharma Sprl |
Crystal structure
|
|
GB201621728D0
(en)
|
2016-12-20 |
2017-02-01 |
Ucb Biopharma Sprl |
Methods
|
|
EP3824906A1
(en)
|
2016-12-21 |
2021-05-26 |
Amgen Inc. |
Anti-tnf alpha antibody formulations
|
|
MX2019008449A
(es)
|
2017-02-08 |
2019-09-09 |
Bristol Myers Squibb Co |
Polipetidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos.
|
|
US11535668B2
(en)
|
2017-02-28 |
2022-12-27 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
CN116836285A
(zh)
|
2017-03-09 |
2023-10-03 |
健玛保 |
针对pd-l1的抗体
|
|
WO2018183366A1
(en)
|
2017-03-28 |
2018-10-04 |
Syndax Pharmaceuticals, Inc. |
Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
|
|
EP3601354A1
(en)
|
2017-03-31 |
2020-02-05 |
Genmab Holding B.V. |
Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
|
|
CA3063362A1
(en)
|
2017-05-12 |
2018-11-15 |
Harpoon Therapeutics, Inc. |
Msln targeting trispecific proteins and methods of use
|
|
CA3063359A1
(en)
|
2017-05-12 |
2018-11-15 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
|
KR20240042244A
(ko)
|
2017-05-19 |
2024-04-01 |
신닥스 파마슈티컬스, 인크. |
조합 요법
|
|
WO2018220207A1
(en)
|
2017-06-01 |
2018-12-06 |
Psioxus Therapeutics Limited |
Oncolytic virus and method
|
|
AU2018291497A1
(en)
|
2017-06-30 |
2020-01-16 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
|
|
WO2019004943A1
(en)
|
2017-06-30 |
2019-01-03 |
Aslan Pharmaceuticals Pte Ltd |
METHOD OF TREATMENT USING ANTIBODY DIRECTED AGAINST IL-13R
|
|
JP7290013B2
(ja)
|
2017-08-04 |
2023-06-13 |
ジェンマブ エー／エス |
Ｐｄ－ｌ１およびｃｄ１３７に結合する結合物質ならびにその使用
|
|
AU2018348429B2
(en)
|
2017-10-10 |
2025-08-28 |
Numab Therapeutics AG |
Multispecific antibody
|
|
EP3470426A1
(en)
|
2017-10-10 |
2019-04-17 |
Numab Therapeutics AG |
Multispecific antibody
|
|
UA129446C2
(uk)
|
2017-10-13 |
2025-04-30 |
Гарпун Терап'Ютікс, Інк. |
Триспецифічні білки і способи їх застосування
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
MX2020006322A
(es)
|
2017-12-19 |
2020-09-18 |
Xencor Inc |
Proteinas de fusion il-2 fc modificadas.
|
|
WO2019122409A1
(en)
|
2017-12-22 |
2019-06-27 |
Argenx Bvba |
Bispecific antigen binding construct
|
|
CN109970856B
(zh)
|
2017-12-27 |
2022-08-23 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
|
GB201802486D0
(en)
|
2018-02-15 |
2018-04-04 |
Ucb Biopharma Sprl |
Methods
|
|
GB201802487D0
(en)
|
2018-02-15 |
2018-04-04 |
Argenx Bvba |
Cytokine combination therapy
|
|
WO2019182996A1
(en)
*
|
2018-03-19 |
2019-09-26 |
The Regents Of The University Of California |
Antibody-interferon fusion proteins for enhancing adoptive t cell therapies for the treatment of cancer
|
|
WO2019179391A1
(en)
*
|
2018-03-19 |
2019-09-26 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Novel bispecific pd-1/ctla-4 antibody molecules
|
|
CN112469477A
(zh)
|
2018-04-04 |
2021-03-09 |
Xencor股份有限公司 |
与成纤维细胞活化蛋白结合的异源二聚体抗体
|
|
AU2019256539A1
(en)
|
2018-04-18 |
2020-11-26 |
Xencor, Inc. |
PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
|
|
EP3781598A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
|
WO2019222283A1
(en)
|
2018-05-14 |
2019-11-21 |
Harpoon Therapeutics, Inc. |
Binding moiety for conditional activation of immunoglobulin molecules
|
|
SG11202012312UA
(en)
|
2018-06-18 |
2021-01-28 |
UCB Biopharma SRL |
Gremlin-1 antagonist for the prevention and treatment of cancer
|
|
GB201811368D0
(en)
|
2018-07-11 |
2018-08-29 |
Ucb Biopharma Sprl |
Antibody
|
|
KR20210044243A
(ko)
|
2018-08-13 |
2021-04-22 |
인히브릭스, 인크. |
Ox40 결합 폴리펩티드 및 이의 용도
|
|
US20210395350A1
(en)
|
2018-08-21 |
2021-12-23 |
Citryll B.V. |
Antibodies binding to citrullinated histone 2a and/or 4
|
|
EP3847196A4
(en)
|
2018-09-07 |
2023-01-04 |
ITabMed (HK) Limited |
BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
EP3856771A4
(en)
|
2018-09-25 |
2022-06-29 |
Harpoon Therapeutics, Inc. |
Dll3 binding proteins and methods of use
|
|
SG11202103192RA
(en)
|
2018-10-03 |
2021-04-29 |
Xencor Inc |
Il-12 heterodimeric fc-fusion proteins
|
|
MA53812A
(fr)
|
2018-10-04 |
2021-08-11 |
Genmab Holding B V |
Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques
|
|
MX2021004351A
(es)
|
2018-10-16 |
2021-05-31 |
UCB Biopharma SRL |
Metodo para el tratamiento de miastenia grave.
|
|
GB201817311D0
(en)
|
2018-10-24 |
2018-12-05 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201817309D0
(en)
|
2018-10-24 |
2018-12-05 |
Ucb Biopharma Sprl |
Antibodies
|
|
CN120983617A
(zh)
|
2018-11-06 |
2025-11-21 |
健玛保 |
抗体配制剂
|
|
GB201900732D0
(en)
|
2019-01-18 |
2019-03-06 |
Ucb Biopharma Sprl |
Antibodies
|
|
TWI756621B
(zh)
*
|
2019-01-25 |
2022-03-01 |
大陸商信達生物製藥（蘇州）有限公司 |
新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體
|
|
EP3930687A4
(en)
|
2019-02-25 |
2023-06-07 |
The University of Chicago |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
|
|
AU2020232605A1
(en)
|
2019-03-01 |
2021-10-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind ENPP3 and CD3
|
|
CN113416258B
(zh)
*
|
2019-10-24 |
2023-08-29 |
北京免疫方舟医药科技有限公司 |
一种多特异性抗体及其制备方法和用途
|
|
EP3816185A1
(en)
|
2019-11-04 |
2021-05-05 |
Numab Therapeutics AG |
Multispecific antibody directed against pd-l1 and a tumor-associated antigen
|
|
GB201917480D0
(en)
|
2019-11-29 |
2020-01-15 |
Univ Oxford Innovation Ltd |
Antibodies
|
|
CN110950967B
(zh)
*
|
2019-12-13 |
2022-05-13 |
山东民康生物科技有限公司 |
抗人血清白蛋白纳米抗体与il-2融合蛋白及制备方法
|
|
GB201919061D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibody
|
|
GB201919058D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibodies
|
|
GB201919062D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Antibody
|
|
GB202001447D0
(en)
|
2020-02-03 |
2020-03-18 |
Ucb Biopharma Sprl |
Antibodies
|
|
WO2021155916A1
(en)
|
2020-02-04 |
2021-08-12 |
BioNTech SE |
Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
|
|
JP7399305B2
(ja)
*
|
2020-02-12 |
2023-12-15 |
イーライ リリー アンド カンパニー |
抗体または抗原結合フラグメントの結晶化
|
|
EP4103610A1
(en)
|
2020-02-13 |
2022-12-21 |
UCB Biopharma SRL |
Anti cd44-ctla4 bispecific antibodies
|
|
WO2021160265A1
(en)
|
2020-02-13 |
2021-08-19 |
UCB Biopharma SRL |
Bispecific antibodies against cd9 and cd137
|
|
EP4103612A1
(en)
|
2020-02-13 |
2022-12-21 |
UCB Biopharma SRL |
Bispecific antibodies against cd9
|
|
EP4103609A1
(en)
|
2020-02-13 |
2022-12-21 |
UCB Biopharma SRL |
Bispecific antibodies against cd9 and cd7
|
|
EP4103611B1
(en)
|
2020-02-13 |
2024-03-27 |
UCB Biopharma SRL |
Bispecific antibodies binding hvem and cd9
|
|
TW202140563A
(zh)
|
2020-02-21 |
2021-11-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
抗ｉｌ－２抗體、其抗原結合片段及其醫藥用途
|
|
IL295448A
(en)
|
2020-02-21 |
2022-10-01 |
Harpoon Therapeutics Inc |
flt3 binding proteins and methods of use
|
|
TWI874613B
(zh)
*
|
2020-03-17 |
2025-03-01 |
美商西雅圖免疫公司 |
微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
|
|
AU2021236906A1
(en)
|
2020-03-18 |
2022-08-18 |
Genmab A/S |
Antibodies binding to B7H4
|
|
IL296732A
(en)
|
2020-03-27 |
2022-11-01 |
UCB Biopharma SRL |
Autonomous knob domain peptides
|
|
CN113461824A
(zh)
*
|
2020-03-31 |
2021-10-01 |
普米斯生物技术(珠海)有限公司 |
一种构建多特异性抗体的平台
|
|
US20230227570A1
(en)
|
2020-05-08 |
2023-07-20 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
CA3182362A1
(en)
|
2020-05-14 |
2021-11-18 |
Jiangsu Hengrui Medicine Co., Ltd. |
Anti-cd25 antibodies, antigen-binding fragments thereof, and medical uses thereof
|
|
EP3915580A1
(en)
|
2020-05-29 |
2021-12-01 |
Numab Therapeutics AG |
Multispecific antibody
|
|
TWI882142B
(zh)
|
2020-07-02 |
2025-05-01 |
大陸商北京拓界生物醫藥科技有限公司 |
抗FXI/FXIa抗體、其抗原結合片段及醫藥用途
|
|
US20230405138A1
(en)
|
2020-07-27 |
2023-12-21 |
Tuojie Biotech (Shanghai) Co., Ltd. |
Anti-cd79b antibody-drug conjugate, and preparation method therefor and pharmaceutical use thereof
|
|
AU2021322046A1
(en)
|
2020-08-06 |
2023-02-02 |
BioNTech SE |
Binding agents for coronavirus S protein
|
|
GB202012326D0
(en)
|
2020-08-07 |
2020-09-23 |
Citryll B V |
Diagnostic
|
|
KR102607909B1
(ko)
|
2020-08-19 |
2023-12-01 |
젠코어 인코포레이티드 |
항-cd28 조성물
|
|
JP2023541860A
(ja)
|
2020-09-10 |
2023-10-04 |
ジェンマブ エー／エス |
びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
|
|
CA3190349A1
(en)
|
2020-09-10 |
2022-03-17 |
Brian Elliott |
Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
|
|
CA3191403A1
(en)
|
2020-10-13 |
2022-04-21 |
Edward Hsia |
Bispecific molecules and methods of treatment using the same
|
|
WO2022079199A1
(en)
|
2020-10-15 |
2022-04-21 |
UCB Biopharma SRL |
Binding molecules that multimerise cd45
|
|
EP3988568A1
(en)
|
2020-10-21 |
2022-04-27 |
Numab Therapeutics AG |
Combination treatment
|
|
CA3197465A1
(en)
|
2020-11-02 |
2022-05-05 |
UCB Biopharma SRL |
Use of anti-trem1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders
|
|
IL303295A
(en)
|
2020-12-07 |
2023-07-01 |
UCB Biopharma SRL |
Multi-specific antibodies and antibody combinations
|
|
AU2021398385A1
(en)
|
2020-12-07 |
2023-07-13 |
UCB Biopharma SRL |
Antibodies against interleukin-22
|
|
PE20250740A1
(es)
|
2021-02-02 |
2025-03-13 |
Numab Therapeutics AG |
Anticuerpos multiespecificos con especificidad para ror1 y cd3
|
|
GB202102227D0
(en)
|
2021-02-17 |
2021-03-31 |
UCB Biopharma SRL |
Antibodies
|
|
JP2024511319A
(ja)
|
2021-03-09 |
2024-03-13 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
|
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
|
|
CN116981477A
(zh)
|
2021-04-25 |
2023-10-31 |
江苏恒瑞医药股份有限公司 |
抗masp2抗体、其抗原结合片段及医药用途
|
|
CN117642428A
(zh)
|
2021-05-03 |
2024-03-01 |
Ucb生物制药有限责任公司 |
抗体
|
|
EP4085973A1
(en)
|
2021-05-04 |
2022-11-09 |
Citryll B.V. |
Inhibition of eosinophil extracellular traps
|
|
IL308223A
(en)
|
2021-05-04 |
2024-01-01 |
Citryll B V |
Prevention of eosinophilic traps
|
|
JP2024519212A
(ja)
|
2021-05-07 |
2024-05-09 |
ジェンマブ エー／エス |
Ｂ７ｈ４およびｃｄ３に結合する二重特異性抗体を含む薬学的組成物
|
|
US20240262924A1
(en)
|
2021-06-21 |
2024-08-08 |
Genmab A/S |
Combination dosage regime of cd137 and pd-l1 binding agents
|
|
CA3223842A1
(en)
|
2021-06-28 |
2023-01-05 |
Yuan Lin |
Anti-cd40 antibody, antigen-binding fragment and medical use thereof
|
|
WO2023285878A1
(en)
|
2021-07-13 |
2023-01-19 |
Aviation-Ophthalmology |
Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
|
|
CN113527503A
(zh)
*
|
2021-07-27 |
2021-10-22 |
福建医科大学 |
一种用于类风湿性关节炎的抗VEGF和TNF-α双特异性纳米抗体融合蛋白
|
|
GB202111905D0
(en)
|
2021-08-19 |
2021-10-06 |
UCB Biopharma SRL |
Antibodies
|
|
EP4393949A4
(en)
|
2021-08-25 |
2025-01-08 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
PHARMACEUTICAL COMPOSITION WITH FUSION PROTEIN
|
|
TW202328195A
(zh)
|
2021-09-15 |
2023-07-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
特異性結合ｐｄ－１的蛋白及其醫藥用途
|
|
JP7503215B2
(ja)
|
2021-10-08 |
2024-06-19 |
ジェンマブ エー／エス |
Ｃｄ３０及びｃｄ３に結合する抗体
|
|
EP4183800A1
(en)
|
2021-11-19 |
2023-05-24 |
Medizinische Hochschule Hannover |
Novel sars-cov-2 neutralizing antibodies
|
|
JP2025508692A
(ja)
|
2022-02-11 |
2025-04-10 |
江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 |
免疫複合体及びその使用
|
|
WO2023174521A1
(en)
|
2022-03-15 |
2023-09-21 |
Genmab A/S |
Binding agents binding to epcam and cd137
|
|
GB202205203D0
(en)
|
2022-04-08 |
2022-05-25 |
UCB Biopharma SRL |
Combination with inhibitor
|
|
GB202205200D0
(en)
|
2022-04-08 |
2022-05-25 |
Ucb Biopharma Sprl |
Combination with chemotherapy
|
|
WO2024038095A1
(en)
|
2022-08-16 |
2024-02-22 |
Iome Bio |
NOVEL ANTI-RGMb ANTIBODIES
|
|
CA3264339A1
(en)
|
2022-08-31 |
2024-03-07 |
Emergent Travel Health Inc |
Alphavirus antigen-binding molecules and their uses
|
|
GB202214756D0
(en)
|
2022-10-07 |
2022-11-23 |
Univ Oxford Innovation Ltd |
Product
|
|
GB202216284D0
(en)
|
2022-11-02 |
2022-12-14 |
Ucl Business Ltd |
Self-regulation
|
|
IL320771A
(en)
|
2022-11-28 |
2025-07-01 |
UCB Biopharma SRL |
Fibromyalgia treatment
|
|
WO2024140903A1
(zh)
|
2022-12-28 |
2024-07-04 |
苏州盛迪亚生物医药有限公司 |
一种cd40结合分子的组合物及医药用途
|
|
EP4442705A1
(en)
|
2023-04-03 |
2024-10-09 |
Citryll B.V. |
Dosage
|
|
TW202506178A
(zh)
|
2023-04-05 |
2025-02-16 |
丹麥商珍美寶股份有限公司 |
包含與ｃｄ３０和ｃｄ３結合之抗體之醫藥組成物
|
|
TW202509077A
(zh)
|
2023-06-30 |
2025-03-01 |
丹麥商珍美寶股份有限公司 |
與纖維母細胞活化蛋白α及死亡受體４結合之抗體
|
|
WO2025036392A1
(zh)
*
|
2023-08-15 |
2025-02-20 |
明慧医药（杭州）有限公司 |
特异性结合cdcp1的单域抗体及其应用
|
|
WO2025056180A1
(en)
|
2023-09-15 |
2025-03-20 |
BioNTech SE |
Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
|
|
AR133903A1
(es)
*
|
2023-09-22 |
2025-11-12 |
Ablynx Nv |
Agentes de unión de albúmina bi- y multivalentes
|
|
GB202316779D0
(en)
|
2023-11-01 |
2023-12-13 |
Ucl Business Ltd |
Antigen binding protein
|
|
GB202318703D0
(en)
|
2023-12-07 |
2024-01-24 |
Citryll B V |
Diagnostic agent
|
|
GB202318820D0
(en)
|
2023-12-08 |
2024-01-24 |
UCB Biopharma SRL |
Antibodies
|
|
WO2025133290A1
(en)
|
2023-12-21 |
2025-06-26 |
Temper Bio |
Protein for immune regulation
|
|
WO2025158009A1
(en)
|
2024-01-26 |
2025-07-31 |
Almirall S.A. |
Bispecific molecules and methods of treatment using the same
|
|
GB202403366D0
(en)
|
2024-03-08 |
2024-04-24 |
Univ Oxford Innovation Ltd |
Product
|
|
WO2025196217A1
(en)
|
2024-03-21 |
2025-09-25 |
UCB Biopharma SRL |
Treatment of tauopathies with tau-binding antibodies
|
|
WO2025238133A1
(en)
|
2024-05-17 |
2025-11-20 |
UCB Biopharma SRL |
Multispecific antibody with binding specificity for il-11 and il-17
|
|
WO2025238135A2
(en)
|
2024-05-17 |
2025-11-20 |
UCB Biopharma SRL |
Antibody with binding specificity for il-11
|